Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
Nav1.2 x PI4K x SIRT1 x hERG x nAChRα9&α10 | 1 |
Mechanism Nav1.2 blockers [+4] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CALCR agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date11 Jan 1999 |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date11 Feb 2011 |
Sponsor / Collaborator |
Start Date01 Feb 2011 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
20(S)-Ginsenoside-Rg3 ( Nav1.2 x PI4K x SIRT1 x hERG x nAChRα9&α10 ) | Alzheimer Disease More | Preclinical |
Genitourinary Disorders program (Unigene) | Urogenital Diseases More | Discontinued |
Inflammation program (Unigene) | Inflammation More | Discontinued |
Metabolic Disease program (Unigene) | Metabolic Diseases More | Discontinued |
PYYNH2 ( NPY receptor ) | Obesity More | Pending |